FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

٨	Vá	3.5	h	iin	atc	n.	D	C.	20	054	9		

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
SIAILMLINI	OF CHANGES	IN DENEFICIAL	CWINEINSTILL

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or S	ection 3	u(ii) of the l	ivestine	III CO	mpany Act o	1940							
	nd Address of RONAL		2. Issuer Name <b>and</b> Ticker or Trading Symbol Rallybio Corp [ RLYB ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					ner		
(Last) (First) (Middle) C/O RALLYBIO CORPORATION 234 CHURCH STREET, SUITE 1020					3. Date of Earliest Transaction (Month/Day/Year) 07/28/2021								Officer (give title Other (specify below)					
(Street) NEW HAVEN CT 06510					4. If Amendment, Date of Original Filed (Month/Day/Year)							(	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
			Table I - Non			_			Dis		<u> </u>		ally O					
1. Title of	Security (Ins	tr. 3)		2. Transa Date [Month/Da	action 2A. Deemed Execution Date, if any (Month/Day/Year)		ıtion Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			and 5) Securities Beneficially Following Re		Owned eported	6. Own Form: (D) or I (I) (Inst	Direct II ndirect E r. 4) C	7. Nature of ndirect Beneficial Ownership
									v	Amount	unt (A) or (D)		:e	Transaction(s) (Instr. 3 and 4)		(1		nstr. 4)
Common Stock 07/2						3/2021		J <sup>(1)</sup>		1,993,93	11 A	(	(1)	1,993,	911			Gee ootnote <sup>(2)</sup>
Common Stock 08/0						2/2021		P		153,84	6 A	\$	13	2,147,757				Gee ootnote <sup>(2)</sup>
Common Stock 08/02					2/2021		P		153,846		\$	\$13 2,301,		.603			Gee ootnote <sup>(3)</sup>	
			Table II - I							osed of, convertib				ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date Securit (Month/Day/Year) Derivat			Securitie Derivativ	. Title and Amount of iecurities Underlying lerivative Security instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitic Benefici Owned Followir Reporte	ve es ially ng	Ownership of Form: Be Direct (D) Ov	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amoui Numbe Shares	er of		Transac (Instr. 4)	tion(s)		
Series A-1 Preferred Units	(1)	07/28/2021		J <sup>(1)</sup>			1,795,946	(1)		(1)	Common Stock <sup>(4)</sup>	282,	,044	(1)	0		I	See footnote <sup>(2)</sup>
Series A-2 Preferred Units	(1)	07/28/2021		J <sup>(1)</sup>			8,742,654	(1)		(1)	Common Stock <sup>(4)</sup>	1,372	2,989	(1)	0		I	See footnote <sup>(2)</sup>
Series B Preferred Units	(1)	07/28/2021		J <sup>(1)</sup>			2,157,838	(1)		(1)	Common Stock <sup>(4)</sup>	338,	,878	(1)	0		I	See footnote <sup>(2)</sup>
Option (Right to Buy)	\$13	07/28/2021		A		13,440		(5)		(5)	Common Stock	13,4	440	\$0.00	13,4	140	D	

- 1. The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the "Preferred Units") reported herein were preferred units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation.
- 2. Shares are directly held by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC) is the general partner of NLVA-III LP. The Reporting Person is a managing director of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Reporting Person disclaims beneficial ownership of the shares held by NLV-III, except to the extent of his pecuniary interest therein, if any.
- 3. Shares are directly held by New Leaf Biopharma Opportunities II, L.P. ("NL BPO-II"). New Leaf BPO Associates II, L.P. ("NL BPOA-II LP") is the general partner of NL BPO-II and New Leaf BPO Management II, L.L.C. ("NL BPOA-II LLC) is the general partner of NL BPOA-II LP. The Reporting Person is a managing director of NL BPOA-II LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NL BPO-II. The Reporting Person disclaims beneficial ownership of the shares held by NL BPO-II, except to the extent of his pecuniary interest therein, if any.
- 4. Prior to the effectiveness of the Plan of Liquidation, the Preferred Units of Rallybio Holdings, LLC were convertible into shares of common units of Rallybio Holdings, LLC.
- 5. The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031.

## Remarks:

By: /s/ Michael Greco, Attorney- 08/04/2021 in-Fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.